Experience with the oral iron chelator deferiprone in transfusion-dependent children
نویسندگان
چکیده
منابع مشابه
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
The identification of a safe, orally active iron chelator is critically important for the prevention of morbidity and early death in patients receiving regular red cell transfusions. Based on our findings in a 1-year multicenter, prospective study of the safety and efficacy of deferiprone in patients with thalassemia major, we have extended the treatment period to 4 years. The mean dose of the ...
متن کاملThe oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice.
PURPOSE To investigate the retinal-protective effects of the oral iron chelator deferiprone (DFP) in mice lacking the iron regulatory hormone hepcidin (Hepc). These Hepc knockout (KO) mice have age-dependent systemic and retinal iron accumulation leading to retinal degeneration. METHODS Hepc KO mice were given DFP in drinking water from age 6 to 18 months. They were then compared to Hepc KO m...
متن کاملEffect of Oral Iron Chelator Deferiprone on Skeletal Radiography of Thalassemia Major Patients
Regular blood transfusion along with iron chelation therapy is a supportive treatment for thalassemia major. Chelation therapy too has its side effects. The most common adverse effects associated with administration of deferiprone are agranulocytosis, neutropenia and arthralgia, primarily, of the large joints. Objective : The study was undertaken to examine the effect of deferiprone on the larg...
متن کاملCombination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
There are few papers on the combination therapy of deferiprone (DFP) and deferasirox (DFX) in iron-overloaded patients with transfusion-dependent β-thalassemia major (β-TM). A total of 6 patients with β-TM (5 males and 1 female) with a mean age of 23.8±5.8 years (ranging from 17 to 31) used this treatment regimen. The mean doses of DFP and DFX were 53.9±22.2 and 29.3±6.8 mg/kg/day, respectively...
متن کاملChelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
BACKGROUND AND OBJECTIVE Excessive hemosiderosis is the main reason for the multi-organ failure observed in multitransfused patients. Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-one, L1) is an orally active iron chelator mainly excreted via urine. We conducted a study in order to determine the efficacy and safety of L1 in Greek thalassemic patients. DESIGN AND METHODS A group of 11 thalass...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Ceylon Medical Journal
سال: 2011
ISSN: 2386-1274,0009-0875
DOI: 10.4038/cmj.v47i4.3413